Drug Trial Radar · NCT06866977
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
Oct 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Xiangya Hospital of Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer.
Conditions
- Pancreatic Cancer
Interventions
Oncolytic virus VRT106Drug
VRT106, IV
ChemotherapyDrug
21 days/cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: About 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.